Last edition
News about "Sun Pharma "
Sun Pharma Launches Semaglutide Injection in India Under Noveltreat and Sematrinity
Sun Pharmaceutical Industries has introduced semaglutide injections in India under the brands Noveltreat and Sematrinity, expanding access to advanced therapies for chronic weight management and type 2 diabetes. The launch strengthens treatment options with multiple dose strengths tailored to patient needs alongside diet and lifestyle interventions.
Sun Pharma | 21/03/2026 | By News Bureau | 335
The US FDA has accepted Sun Pharma’s supplemental BLA for ILUMYA to treat active psoriatic arthritis in adults, with a decision expected by 29 October, 2026, potentially expanding its IL-23 inhibitor portfolio.
Sun Pharma | 17/03/2026 | By News Bureau
MHRA Clears Deuruxolitinib (Leqselvi) by Sun Pharma for Severe Alopecia Areata in Adults
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved deuruxolitinib (Leqselvi) for treating severe Alopecia Areata in adults, granting authorisation to Sun Pharma UK via the International Recognition Procedure (IRP).
Sun Pharma | 13/03/2026 | By News Bureau
Sun Pharma to Invest Rs 500 Crore in Expansion of Assam Manufacturing Unit
Sun Pharmaceutical Industries said it will invest Rs 500 crore to expand its manufacturing facility in Assam, aiming to strengthen its domestic production infrastructure and support future growth.
Sun Pharma | 06/02/2026 | By Darshana | 164
Sun Pharma Wins DCGI Nod for Generic Semaglutide Injection
Sun Pharmaceutical has secured approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic semaglutide injection for chronic weight management, paving the way for its entry into the fast-growing obesity treatment segment once the semaglutide patent expires in the country.
Sun Pharma | 27/01/2026 | By News Bureau | 145
Sun Pharma Launches UNLOXCYT for Advanced Cutaneous Squamous Cell Carcinoma
Sun Pharma has announced the US availability of UNLOXCYT for adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not eligible for curative surgery or radiation. The updated label includes long-term data supporting durable efficacy and a favourable tolerability profile.
Sun Pharma | 16/01/2026 | By News Bureau
Sun Pharma Introduces ILUMYA in India for Plaque Psoriasis Treatment
Sun Pharma has launched its global innovative drug, ILUMYA (Tildrakizumab), in India for the treatment of moderate-to-severe plaque psoriasis.
Sun Pharma | 01/12/2025 | By Dineshwori | 156
US FDA Approves Label Update for Sun Pharma's UNLOXCYT
Sun Pharma has received US FDA approval for a label update to UNLOXCYT, the first and only PD-L1 inhibitor for advanced Cutaneous Squamous Cell Carcinoma (aCSCC), further supporting its clinical value with durable responses and a favourable safety profile for patients with multiple comorbidities.
Sun Pharma | 27/11/2025 | By Dineshwori | 138
AstraZeneca and Sun Pharma have entered into a second exclusive brand partnership to expand access to Sodium Zirconium Cyclosilicate (SZC) in India for the management of Hyperkalaemia.
Sun Pharma | 17/11/2025 | By Dineshwori | 560
Sun Pharma Presents Two Posters on Utreglutide at ObesityWeek 2025
Sun Pharma presented new clinical data on its investigational GLP-1 agonist, Utreglutide, at ObesityWeek 2025, highlighting meaningful reductions in body weight, waist circumference, and lipid parameters across two studies, with the therapy showing a favourable and class-consistent safety profile.
Sun Pharma | 14/11/2025 | By Dineshwori | 319
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy